Mumbai, Nov. 7 -- Revenue from operations jumped 24.27% year-on-year to Rs 6,831.43 crore in the quarter ended 30 September 2025.

Profit before tax stood at Rs 2,006.97 crore during the quarter, up 90.25% from Rs 1,054.86 crore recorded in Q2 FY25.

EBITDA stood at Rs 2,431.3 crore in Q2 FY26, registering 75.8% growth compared with Rs 1,382.7 crore in Q2 FY25. The EBITDA margin improved 1,040 basis points to 35.6% in Q2 FY26 from 25.2% in Q2 FY25.

U.S. sales for Q2 FY26 were Rs 2,762.4 crore, up 47.3% compared to Rs 1,875.3 crore in Q2 FY25, accounting for 40% of Lupin's global sales. The company received six ANDA approvals from the U.S. FDA and launched six products in the U.S. market during the quarter. Lupin now has 147 generic produ...